Publicacions (41) Publicacions de ÁNGEL CUESTA MARTÍNEZ

2024

  1. CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis

    Cancer Letters, Vol. 588

  2. Endothelial-to-Mesenchymal Transition in an Hereditary Hemorrhagic Telangiectasia-like Pediatric Case of Multiple Pulmonary Arteriovenous Malformations

    International Journal of Molecular Sciences, Vol. 25, Núm. 11

  3. Molecular and Cellular Characterization of Primary Endothelial Cells from a Familial Cavernomatosis Patient

    International Journal of Molecular Sciences, Vol. 25, Núm. 7

2023

  1. Mutation in Chek2 triggers von Hippel-Lindau hemangioblastoma growth

    Acta Neurochirurgica, Vol. 165, Núm. 12, pp. 4241-4251

  2. New and Old Key Players in Liver Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

2022

  1. A Novel Splicing Mutation in the ACVRL1/ALK1 Gene as a Cause of HHT2

    Journal of Clinical Medicine, Vol. 11, Núm. 11

  2. C3G down-regulation enhances pro-migratory and stemness properties of oval cells by promoting an epithelial-mesenchymal-like process

    International journal of biological sciences, Vol. 18, Núm. 15, pp. 5873-5884

  3. Hereditary Hemorrhagic Telangiectasia: Diagnosis and Management

    Journal of Clinical Medicine

  4. Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    Journal of Clinical Medicine, Vol. 11, Núm. 15

  5. The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases

    International Journal of Molecular Sciences, Vol. 23, Núm. 8

2020

  1. CLN5 in heterozygosis may protect against the development of tumors in a VHL patient

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

  2. Review of pharmacological strategies with repurposed drugs for hereditary hemorrhagic telangiectasia related bleeding

    Journal of Clinical Medicine, Vol. 9, Núm. 6, pp. 1-22

  3. Targeting β2-adrenergic receptors shows therapeutical benefits in clear cell renal cell carcinoma from von Hippel–Lindau disease

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-30

2019

  1. Deep Learning Reveals Cancer Metastasis and Therapeutic Antibody Targeting in the Entire Body

    Cell, Vol. 179, Núm. 7, pp. 1661-1676.e19

  2. Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: Phase III clinical trial

    BMJ Open Ophthalmology, Vol. 4, Núm. 1

  3. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

    Nature Communications, Vol. 9, Núm. 1

  2. PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFa

    Cancer Research, Vol. 78, Núm. 7, pp. 1805-1819

2016

  1. EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance

    Nature Communications, Vol. 7

  2. Intramolecular trimerization, a novel strategy for making multispecific antibodies with controlled orientation of the antigen binding domains

    Scientific Reports, Vol. 6